Jason Ryan has hopped from Foundation to Medicine to Magenta Therapeutics after playing a key role in Foundation’s $2.4 billion buyout by Roche.
Results from Aimmune’s phase 3 trial of AR101 for peanut allergy have been published and bode well for its planned FDA filing next month.
In 1848, the most famous Gold Rush in American history began at Sutter's Mill near present-day Coloma, California, shaping the US economic map forever. In…
The Forbion-led series B tees up Inflazome to trial its NLRP3 inflammasome inhibitors in several inflammatory diseases.
The deal gives the Roche subsidiary at least a partial stake in the preclinical MAGE-A4-targeting drug IMC-C103C.
Quanterix is expanding its blood biomarker testing business into oncology, with early access to its benchtop imager and a new 10-plex assay.
Neurodegenerative disease startup QurAlis has extended the seed round it first announced in April, bringing its total funding up to $5.5 million.
Johnson & Johnson Vision inked a $26.35 million collaboration with the Singapore Eye Research institute focused on treating nearsightedness.
Antimalarial drugs known as chloroquines play a role in inhibiting cancer cell growth by targeting the enzyme PPT1, researchers discovered.
Camel-IDS will run a phase 1b/2 trial of its lead radiopharmaceutical in HER2-positive breast cancer that has spread to the brain.
WuXi AppTec opened a new medical device testing facility just outside Shanghai in Suzhou, China.
